WHO Reviews Treatment and Vaccine Options

Why are new options needed for Bundibugyo Ebola?

Ebola disease can be caused by several virus species, including Zaire ebolavirus and Bundibugyo virus. Antibody medicines work by recognizing particular viral targets, so differences between species matter clinically. WHO’s expert consultation focuses on identifying candidate interventions that could be evaluated responsibly for Bundibugyo Ebola rather than assuming that products developed for Zaire ebolavirus will provide the same protection.

The U.S. Food and Drug Administration has approved the monoclonal-antibody treatments Inmazeb and Ebanga for Ebola disease caused by Zaire ebolavirus. Those approvals were based on clinical evidence in that specific setting. They remain important advances in Ebola care, but their labeled use does not establish effectiveness against Bundibugyo virus.

How are Ebola treatments and vaccines evaluated during an outbreak?

Candidate countermeasures are usually prioritized using evidence from laboratory studies, animal research, early human safety studies and, where possible, clinical trials. WHO guidance emphasizes that supportive care remains essential while evidence is gathered: early treatment of dehydration, electrolyte imbalance, low oxygen levels and co-infections can improve the chance of survival.

Research during an Ebola outbreak must also be practical. A proposed vaccine or treatment needs a realistic delivery plan, informed consent processes and monitoring for safety. Adaptive trial designs may help researchers compare promising options while allowing protocols to respond to emerging evidence, but they do not remove the need for reliable outcome data.

What should clinicians and the public understand now?

People with possible Ebola symptoms after a relevant exposure need urgent evaluation through public-health and clinical services. Ebola symptoms can begin with fever, fatigue, muscle pain, headache and sore throat, then progress to vomiting, diarrhea or bleeding in some patients. Symptoms overlap with many other illnesses, so testing and infection-control measures are critical.

For the public, the key message is that scientific review of candidate products is not the same as an authorization or proof of benefit. Decisions about vaccination or treatment should follow guidance from health authorities and trained clinical teams. Clear communication about what is known, uncertain and under study is especially important when new countermeasures are discussed.